Dr. Portell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1240 Lee St
Charlottesville, VA 22908Phone+1 434-924-9333Fax+1 434-244-7526
Summary
- Dr. Craig Portell is an oncologist in Charlottesville, VA and is affiliated with Emily Couric Clinical Cancer Center and University of Virginia Medical Center. He received his medical degree from St Louis University School of Medicine and has been in practice 11 years. He specializes in hematologic oncology and is experienced in immunotherapy, chronic lymphoid leukemia, mantle cell lymphoma, waldenstrom's macroglobulinemia, and Non-Hodgkin Lymphoma.
Education & Training
- Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2010 - 2013
- Loyola University Medical CenterResidency, Internal Medicine, 2006 - 2009
- Saint Louis University School of MedicineClass of 2006
Certifications & Licensure
- VA State Medical License 2013 - 2026
- OH State Medical License 2010 - 2014
- IL State Medical License 2006 - 2011
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL Start of enrollment: 2015 Apr 01
- Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy Start of enrollment: 2017 Dec 27
- Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Start of enrollment: 2018 Mar 06
- Join now to see all
Publications & Presentations
PubMed
- 217 citationsPostibrutinib outcomes in patients with mantle cell lymphoma.Peter Martin, Kami J. Maddocks, John P. Leonard, Jia Ruan, Andre Goy
Blood. 2016-03-24 - 72 citationsClinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemiaCraig A. Portell, Candice M. Wenzell, Anjali S. Advani
Clinical Pharmacology. 2013-04-12 - 48 citationsCOVID-19 in patients with CLL: improved survival outcomes and update on management strategies.Lindsey E. Roeker, Toby A. Eyre, Meghan C. Thompson, Nicole Lamanna, Alexander Coltoff
Blood. 2021-07-23
Journal Articles
- The Phase 3 DUO Trial: Duvelisib Versus Ofatumumab in Relapsed and Refractory CLL/SLLMatthew S Davids, Ian W Flinn, Craig A Portell, Nicole Lamanna, Scott Lunin, Amanda F Cashen, Blood
Abstracts/Posters
- Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular TherapiesCraig A. Portell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu...Craig A. Portell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...Craig A. Portell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
- When Chemo Failed, CAR T-cell Therapy Took Away a Father’s CancerSeptember 22nd, 2022
- Venetoclax with Standard Chemo-Immunotherapy Induced a High Response Rate as First-Line Treatment for Mantle Cell Lymphoma and Was Generally Well Tolerated, a PrECOG Early-Phase Trial ShowsDecember 13th, 2023
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: